Merus BV (MRUS) Stock
MRUS is no longer traded. Merus BV was acquired by Genmab in December 2025.
Each MRUS share was exchanged for $97.00 in cash. Prices on this page are historical; the last trade was December 26, 2025 at $96.92.
Merus BV stock price history
MRUS final trading statistics
- Final close
- $96.92
- Final trading day
- Dec 26, 2025
- Market cap at delisting
- $7.35B
- Shares outstanding
- 75.85M
- Final 52-week range
- $33.19 – $97.14
- Avg. volume (final 3 mo.)
- 2,495,393
- All-time high (split-adj.)
- $97.01 · Dec 2025
- All-time low (split-adj.)
- $7.62 · May 2016
- Return since IPO
- +865.3%
- Beta
- 1.06
- Book value / share
- $10.22
- Price / book
- 9.49
Merus BV annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $34.88M | -$207.9M | -$3.35 |
| FY2023 | $39.81M | -$140.3M | -$2.99 |
| FY2022 | $38.84M | -$122.5M | -$2.90 |
| FY2021 | $43.15M | -$58.7M | -$1.72 |
| FY2020 | $24.51M | -$70.0M | -$2.86 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
Merus BV stock FAQ
What happened to Merus BV stock?
Merus BV was acquired by Genmab in December 2025. Shareholders received $97.00 in cash for each share. MRUS stock stopped trading on the Nasdaq, with a final close of $96.92 on December 26, 2025.
What did Merus BV shareholders receive?
Each MRUS share was converted into $97.00 in cash. The deal was valued at about $8 billion.
Is MRUS stock still trading?
No. MRUS was delisted from the Nasdaq in December 2025 and no longer trades on a U.S. exchange.
What was the last price of MRUS stock?
MRUS closed at $96.92 on its final trading day, December 26, 2025, for a market value of about $7.35B.
What were Merus BV's revenue and earnings in its last full fiscal year?
Merus BV reported revenue of $34.88M and net income of -$207.9M in fiscal 2024, its last full year as a public company.
When did Merus BV go public?
Merus BV stock began trading on May 19, 2016.